3Watson WA,Litovitz T L,Rodgtrs G C,et al.2002 Annual report of the American Association of Poison control centers toxic Exposure surveillance System[J].Am J Emerg med,2003.21(5):353-421. 被引量：1
4Gehr Tw,Sica DA Pharmacotherapy in congestive heart failure hyperkalemia in congestive heart failure[J].congest heart fail,2001.7(2):97-100. 被引量：1
5Fogari R,preti P,Derosa G,et al.Fffect of antihypertensive treatment with valsarton or atenolol on sexual activity and plasma testosterone in hyptrtensive men[J]Eur J,clin pharmacol 2002,58(3):177-180. 被引量：1
3Zicha S, Tsuji Y, Shiroshita-Takeshita A, et al. Betablockers as antiarrhythmic agents [J]. Handb Exp Pharmacol, 2006, (171):235-266. 被引量：1
4Watson WA, Litovitz TL, Rodgers GC, et al. 2002 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System[J]. Am J Emerg Med, 2003, 21(5):353-421. 被引量：1
5DeWitt CR, Waksman JC. Parmacology, pathophysiology and management of calcium channel blocker and beta-blocker toxicity[J]. Toxicol Rev, 2004, 23(4):223-238. 被引量：1
6Olson KR, Erdman AR, WoolfAD, et al. Calcium channel blocker ingestion: an evidence-based consensus guideline for out-of-hospital management [J]. Clin Toxicol (Phila), 2005, 43(7):797-822. 被引量：1
7Edoute Y, Nagachandran P, Svirski B, et al. Cardiovascular adverse drug reaction associated with combined beta-adrenergic and calcium entry-blocking agents [J]. J Cardiovasc Pharmacol, 2000,35(4):556-559. 被引量：1
8Savage PJ, Pressel SL, Curb JD, et al. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group[J]. Arch Intem Med, 1998, 158(7):741-751. 被引量：1
9Franse LV, Pallor M, Di Bari M, et al. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program[J]. Hypertension, 2000,35(5): 1025-1030. 被引量：1
10Gehr TW, Sica DA. Pharmacotherapy in congestive heart failure: Hyperkalemia in congestive heart failure [J]. Congest Heart Fail, 2001, 7(2):97-100. 被引量：1
5Moriyama T, Karasawa A. Cardiovescular effects of benidipine and am- lodipine in isolated tissue and anesthetizeddogs [ J ]. Biol pharm bull, 1994, 17(II): 1 468. 被引量：1
6Tamsma J T,Jazet I M,Beishuizen E D,et al.The metabolic syndrome:a vascular perspective[J].Eur J Intern Med,2005,16(5):314-320. 被引量：1
7Brener B M,Cooper M E,De Zeeuw D,et al.Effects of losartanon renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy[J].N Engl J Med,2001,345(12):861-869. 被引量：1
8Sever P S,Dahlof B,Poulter N R,et al.Prevention of coronary and stroke events with atrovastation in hypertensive patients who have average or lower-than-average cholesterol concentrations,in the Anglo-scandinavian cardiac outcomes trial-lipid lowering arm(ASCOT-LLA):a milticentre randomised controlled trial[J].Lancet,2003,361(9364):1149-1158. 被引量：1
9The ALLHAT Officer and Coordinators for the ALLHAT Collaborative Research Group.Major outcomes in moderately hypercholesterolemic,hypertensive patients randomized to pravastatin vs usual care.The antihypertensive and lipid-lowering treatment to prevent heart attack trial(ALLHAT-LLT)[J].JAMA,2002,288(23):2998-3007. 被引量：1
10Yamada H,Suga N,Maeda K,et al.Effects of combination therapy with angiotensinⅡtype 1 receptor blockers and calcium channel blookers on renal function in hypertensive patients/a retrospective“real-world”comparative study[J].Arzneimittelforschung,2010,60(2):64-70. 被引量：1
